Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
April 18, 2024
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO(TM) Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
July 6, 2021
